Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (63)	3/13/2002 8:37:13 AM
From: mopgcw	Read Replies (1) \| Respond to of 139

Progenics Pharma 4Q Loss 36c/Share DOW JONES NEWSWIRES Progenics Pharmaceuticals Inc. - Tarrytown, N.Y. 4th Quar Dec. 31: 2001 2000 Revenue $2,667,453 $3,522,976 Net income (4,478,866) (2,463,376) Shr earns Net income (.36) (.20) Year: Revenue 12,232,040 13,949,429 Net income (1,898,150) (5,917,156) Shr earns Net income (.15) (.49) Figures in parentheses are losses. Progenics Pharmaceuticals Inc. (PGNX), a biopharmaceutical company, received a $9.8 million payment in 2001 in connection with the termination of its collaboration with Bristol-Myers Squibb Co. (BMY). Company Web site: progenics.com